Ep 24: SECOMBIT

Summary James is ill (apparent in his voice)! Find out what gets James to show up to an ASCO meeting, and stay tuned for the fact check to hear the infamous tweet from Omid Hamid regarding James' scrubs. In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel discuss sequencing of immunotherapy and targeted therapy for BRAF-positive melanoma. They review the SECOMBIT study 4-year update from Nature Communications. The sandwich approach is unpacked as an approach to debulk the tumor and increase immune fitness of the patient. They also review lactate dehydrogenase as a selection criteria for treatment, the role of LDH, the phrase 'par excellence', the difference in impact factor between Nature journals, CNS incidence and autopsy series. Keywords SECOMBIT trial, BRAF positive melanoma, lactate dehydrogenase, LDH, immunotherapy, targeted therapy, CNS incidence, autopsy series Titles The Role of LDH CNS Incidence and Autopsy Series Sound Bites "You're rocking the scrubs" "How to define par excellence" "Difference in impact factor"